Company intelligence / Profile preview

Tayu Huaxia Biotech

Ownership: Private
Development stage: Other

Overview

Tayu Huaxia Biotech is a Beijing-based private biotech/pharma company focused on first-in-class immunotherapy drugs, particularly monoclonal antibodies targeting cancer and immune-related indications. Its lead asset TY‑101, an anti-PD‑1 monoclonal antibody for advanced lymphoma and solid tumors, is in a multicenter Phase 1/2 clinical trial. The company has additional assets at preclinical and discovery stages across oncology and immune system diseases.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyBispecific monoclonal antibodyBiological products
Industry: Biotech

Beyond the preview

Go deeper on Tayu Huaxia Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tayu Huaxia Biotech.

Explore the full profile